A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 355-361

  Kang, Yoon Koo ^a   Muro, Kei ^b   Ryu, Min Hee ^a   Yasui, Hirofumi ^c   Nishina, Tomohiro ^d   Ryoo, Baek Yeol ^a   Kamiya, Yukimasa ^e   Akinaga, Shiro ^e   Boku, Narikazu ^c  

^a University of Ulsan College of Medicine   (South Korea)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

ARQ 197; c Met inhibitor; Gastric cancer; Phase II study; Tivantinib

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; C MET GENE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DISEASE CONTROL RATE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ETHNIC GROUP; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTRECTOMY; GASTRIC STENOSIS; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERURICEMIA; JAPANESE; KOREAN; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; MALAISE; MALE; METASTATIC GASTRIC CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; ONCOGENE; ONCOLOGICAL PARAMETERS; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SINGLE DRUG DOSE; STENOSIS; STOMACH CANCER; SURVIVAL TIME; VOMITING;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84896404764     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0057-2     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F et al. (2008) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, 12/2010 update. http://globocan.iarc.fr
2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
3. Wesolowski R, Lee C, Kim R (2009) Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 10:903-912
4. Gherardi E, Birchmeier W, Birchmeier C et al (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89-103
5. Lee J, Seo JW, Jun HJ et al (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517-1524
6. Amemiya H, Kono K, Itakura J et al (2002) c-Met expression in gastric cancer with liver metastasis. Oncology 63:286-296
7. Graziano F, Galluccio N, Lorenzini P et al (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29:4789-4795
8. Lennerz JK, Kwak EL, Ackerman A et al (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803-4810
9. Han SU, Lee JH, Kim WH et al (1999) Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 23:1176-1180
10. Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9:314-326
11. Munshi N, Jeay S, Li Y et al (2010) ARQ 197, a novel and selective inhibitor of the human cMet receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544-1553
12. Eathiraj S, Palma R, Volckova E et al (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 286:20666-20676
13. Sequist LV, von Pawel J, Garmey EG et al (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307-3315
14. Santoro A, Rimassa L, Borbath I et al (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55-63
15. Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44:1083-1105
16. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
17. Yamamoto N, Murakami H, Nishina T et al (2013) The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol 24:1653-1659
18. Kang JH, Lee SI, do Lim H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518
19. Wu CW, Li AF, Chi CW et al (1998) Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5:817-822
20. Rodig S, Sequist LV, Schiller JH et al. (2012) An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study. Cancer Res 72(8 Suppl): abstract 1729
21. Trojan J, Zeuzem S (2013) Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs 22:141-147
22. Kawakami H, Okamoto I, Arao T et al (2013) MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 4:9-17
23. Catenacci DV, Henderson L, Xiao SY et al (2011) Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 1:573-579
24. Yap TA, Olmos D, Brunetto AT et al (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271-1279
25. Rosen LS, Senzer N, Mekhail T et al (2011) A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754-7764